|Bid||20.18 x 800|
|Ask||20.25 x 1400|
|Day's Range||19.85 - 20.33|
|52 Week Range||17.80 - 32.46|
|Beta (3Y Monthly)||2.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.71|
Editas Medicine, Inc. (EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia. Under the terms of the agreement, Editas Medicine obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop up to five therapies including four immuno-oncology therapies, and in return MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.
CAMBRIDGE, Mass., Oct. 01, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following.
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
CRISPR is a gene-editing technique that enables the targeting and editing of specific sequences in the human DNA. It has been around for a couple of years, and recently, researchers in the U.S. have started using it to alter the genes of adults suffering from progressive disorders and diseases. The scientific community largely shunned the experiment, as CRISPR is known to result in unwanted gene edits, which, in the case of embryos (as well as sperm and eggs), are carried over to their offspring.
Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif., Aug. 12, 2019 -- Dynavax.
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in.
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
CAMBRIDGE, Mass., July 30, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the Brilliance Phase 1/2 clinical trial of AGN-151587 (EDIT-101) is open for patient enrollment. AGN-151587 is an experimental medicine under development for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited form of blindness caused by mutations in the CEP290 gene. The clinical trial will be the world’s first in vivo study of a CRISPR-based genome editing medicine, where the editing takes place inside the human body.